This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The EMBARK Phase 3 study for Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, was published this month in Nature Medicine. The paper largely reiterates what’s already known about the negative study — Elevidys failed to achieve its primary endpoint of improving overall muscle function.
But when the paper discussed Elevidys’ impact on secondary muscle-function endpoints — the results that Sarepta touted as demonstrating the gene therapy’s benefit for patients — the EMBARK authors diverged from the company line.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
